An animal model of female adolescent cannabinoid exposure elicits a long-lasting deficit in presynaptic long-term plasticity

Neuropharmacology. 2015 Dec:99:242-55. doi: 10.1016/j.neuropharm.2015.04.034. Epub 2015 May 13.

Abstract

Cannabis continues to be the most accessible and popular illicit recreational drug. Whereas current data link adolescence cannabinoid exposure to increased risk for dependence on other drugs, depression, anxiety disorders and psychosis, the mechanism(s) underlying these adverse effects remains controversial. Here we show in a mouse model of female adolescent cannabinoid exposure deficient endocannabinoid (eCB)-mediated signaling and presynaptic forms of long-term depression at adult central glutamatergic synapses in the prefrontal cortex. Increasing endocannabinoid levels by blockade of monoacylglycerol lipase, the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol (2-AG), with the specific inhibitor JZL 184 ameliorates eCB-LTD deficits. The observed deficit in cortical presynaptic signaling may represent a neural maladaptation underlying network instability and abnormal cognitive functioning. Our study suggests that adolescent cannabinoid exposure may permanently impair brain functions, including the brain's intrinsic ability to appropriately adapt to external influences.

Keywords: Adolescent cannabis abuse; CB1R; Cannabinoids; LTD; mGluR2/3.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoxazines / toxicity
  • Cannabinoid Receptor Agonists / toxicity
  • Cognition Disorders / chemically induced
  • Cognition Disorders / metabolism
  • Disease Models, Animal
  • Endocannabinoids / metabolism
  • Female
  • Long-Term Potentiation / drug effects*
  • Long-Term Potentiation / physiology
  • Marijuana Abuse / physiopathology*
  • Marijuana Abuse / psychology
  • Mice, Inbred C57BL
  • Morpholines / toxicity
  • Naphthalenes / toxicity
  • Prefrontal Cortex / drug effects*
  • Prefrontal Cortex / growth & development*
  • Prefrontal Cortex / physiopathology
  • Presynaptic Terminals / drug effects*
  • Presynaptic Terminals / physiology
  • Receptor, Cannabinoid, CB1 / agonists*
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptors, Metabotropic Glutamate / metabolism
  • Recognition, Psychology / drug effects
  • Recognition, Psychology / physiology
  • Tissue Culture Techniques

Substances

  • Benzoxazines
  • CNR1 protein, mouse
  • Cannabinoid Receptor Agonists
  • Endocannabinoids
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor 2
  • metabotropic glutamate receptor 3
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone